Actos Side Effects | Actos Recall France

Oregon Man Files Actos Side Effects Lawsuit

Seth Harris | April 19th, 2012

Frederick Jackson, of South Beach, Oregon, has filed an Actos bladder cancer lawsuit against Takeda Pharmaceuticals for injuries he sustained as a consequence of using the company’s Type II diabetes medication. Jackson’s suit was filed on April 6, 2012, in the Circuit Court of Cook County, Illinois, where many similar Actos side effects lawsuits have been filed.

Lawsuit alleges Takeda concealed Actos cancer risk

In his multi-count complaint, Jackson alleges that he began taking Actos as a treatment for his diabetes in February of 2008. Just over two years later, in April of 2010, he was diagnosed with bladder cancer. He alleges that although Takeda knew or should have known of the drug’s risks, neither he nor his medical providers were aware of the dangerous Actos side effects, which provoked an Actos recall in Europe.

He states that if he had known of the risk of Actos cancer, he would never have taken the drug. Jackson also points out that while there has been an Actos recall in France, Takeda continues to sell its potentially dangerous drug in the United States. Doing so, he suggests, shows that the company puts profits before patient safety. Jackson has requested a jury trial.

Significant Actos side effects prompt demands for U.S. Actos recall

Since 2005, medical researchers have determined that there is a statistically significant link between the use of Actos and bladder cancer. In 2005, the results of a three-year study (known as the PROactive Study) were published in The Lancet. Though the study was designed to examine cardiovascular side effects, the researchers also found that Actos users had higher rates of bladder cancer than patients who used other drugs. A three-year liver safety study also revealed high rates of Actos bladder cancer.

In 2010, though stopping well short of implementing an Actos recall, the FDA issued a Safety Announcement based on data from an ongoing ten-year study. The FDA reported that the risk of bladder cancer increased significantly after 24 months of Actos use. In 2011, the FDA announced that “use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer.”

In the wake of these and other studies, France and Germany suspended sales of the drug, and in 2011, an Actos recall was announced in France. As of yet, there has been no Actos recall in the United States.